Balance Sheet

v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Current assets:    
Cash $ 577,010 $ 11,342
Accounts receivable, net 36,000 29,950
Prepaid expenses 1,139 13,210
Total current assets 614,149 54,502
Property and equipment, net 45,790 19,012
Other assets:    
Intellectual property, net 250,000 251,963
Deposits, long term 13,422 13,422
Total other assets 263,422 265,385
Total assets 923,361 338,899
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $32,318 and $62,241, respectively 1,225,232 1,199,536
Deferred revenue, short term 236,648 237,347
Settlement payable 15,000
Convertible notes payable, short term portion, net of debt discount 2,753,791
Notes payable, net of debt discount, short term portion 246,337
Notes payable, related party 186,590 186,590
Total current liabilities 4,648,598 1,638,473
Long term debt:    
Deferred revenue, long term 284,347 401,346
Convertible notes payable, long term, net of debt discount 2,016,041
Warrant liability 175,975
Total long term debt 284,347 2,593,362
Total liabilities 4,932,945 4,231,835
Commitments and contingencies
Deficit:    
Preferred stock value 16,000 16,000
Common stock, $0.001 par value; 750,000,000 shares authorized, 247,186,285 and 244,086,285 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively 247,186 244,086
Common stock subscribed 1,250,000 100,000
Additional paid in capital 45,359,506 44,581,896
Accumulated deficit (50,887,847) (48,840,534)
Total stockholders' deficit attributable to BioCorRx, Inc. (4,009,539) (3,892,936)
Non-controlling interest (45)
Total deficit (4,009,584) (3,892,936)
Total liabilities and deficit 923,361 338,899
Series B Preferred Stock [Member]    
Deficit:    
Preferred stock value $ 5,616 $ 5,616

Source